Research work · 2014
Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.
Andrea Borghese Apolo, Yusuke Tomita, Min-Jung Lee, Sunmin Lee, Ari Frosch, Seth M. Steinberg, James L. Gulley, Jeffrey Schlom, Donald Paul Bottaro, Jane B. Trepel
Journal of Clinical Oncology
Abstract
4501 Background: Myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg) are major components of the immune suppressive tumor microenvironment. Both cell types promote effector T-cell dysfunction and tumor progression. The effect of cabozantinib, a tyrosine kinase inhibitor primarily targeting MET and VEGFR2 on specific immunosuppressive subsets, is unclear. In this study we assess MDSC and Tregs in patients undergoing treatment with cabozantinib and correlate with clinical response to therapy. Methods: Peripheral blood samples were obtained from patients with advanced/refractory metastatic urothelial carcinoma undergoing treatment with cabozantinib under a clinical trial at the National Cancer Institute (NCT01688999). MDSC (CD11b+CD33+CD14-) and Tregs (CD4+CD25hi Foxp3+) were measured in 24 patients at baseline and after 2 cycles of continuous cabozantinib treatment. MDSC and Tregs were further analyzed for CD40 and PD-1, respectively, as suppressive functional markers. Results: Patients with low Tregs at baseline had an improved partial response (PR) rate (p=0.014), progression free survival (PFS) (p=0.059) and overall survival (OS) (p=0.0071). Tregs decreased with cabozantinib treatment (p=0.015). Overall, PD-1 expression in Tregs increased after cabozantinib (p=0.011). However, patients with a PD-1 change below the median showed a strong trend to improved PFS compared to those with increased PD-1 above the median (p=0.035). The percent MDSC did not change with treatment. However, MDSC CD40 expression was increased after cabozantinib treatment compared to baseline (p=0.0005). Though, a decrease in MDSC CD40 expression after treatment was associated with an improved PFS (p=0.020). Conclusions: Treg levels prior to cabozantinib treatment are predictive of therapeutic responsiveness and OS. Changes in Treg PD-1 expression and MDSC CD40 expression may be prognostic markers in patients with advanced/refractory metastatic urothelial carcinoma treated with cabozantinib.